Bicara Therapeutics (BCAX) closed at $8.65 on November 6, 2026, up 5.6% from the previous close, on volume of 922,972 shares (30-day average 1,557,700).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 20, 2026 | Straddle or Synthetic | 18-Dec-2620 C : 20 P | 600 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Wed, 4-Nov 8:30 AM ET)
Globe Newswire (Mon, 2-Nov 8:30 AM ET)
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 14-Aug 8:30 AM ET)
Globe Newswire (Tue, 11-Aug 7:30 AM ET)
Market Chameleon (Mon, 11-May 5:21 AM ET)
Market Chameleon (Wed, 25-Feb 4:07 AM ET)
Market Chameleon (Mon, 13-Oct 3:56 AM ET)
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
Bicara Therapeutics trades on the NASDAQ stock market under the symbol BCAX.
As of November 6, 2026, BCAX stock price climbed to $8.65 with 922,972 million shares trading.
BCAX has a beta of 1.28, meaning it tends to be more sensitive to market movements. BCAX has a correlation of 0.04 to the broad based SPY ETF.
BCAX has a market cap of $572.40 million. This is considered a Small Cap stock.
The top ETF exchange traded funds that BCAX belongs to (by Net Assets): VTI, IWM, XBI, VXF, VTWO.
BCAX has underperformed the market in the last year with a price return of -40.6% while the SPY ETF gained +10.8%. BCAX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -68.6% and -49.3%, respectively, while the SPY returned -4.1% and -3.2%, respectively.
BCAX support price is $7.78 and resistance is $8.60 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BCAX shares will trade within this expected range on the day.
